PDF(Pubmed)
Abstract：
BACKGROUND: There is limited data on the incidence of gastrointestinal-specific pathology in gender non-conforming (GNC) populations.
METHODS: Retrospective analysis of pancreatitis incidence rates in transgender and GNC persons exposed and not exposed to gender-affirming hormone therapy (GAHT).
RESULTS: 7 of the 1333 patients on hormone therapy had an incidence of pancreatitis. 0 of the 615 patients with no history of GAHT use developed pancreatitis. Representing a 6.96 (95% CI 2.76 to 848.78) for the development of pancreatitis in patients with exposure to GAHT therapy.
CONCLUSIONS: Clinicians working with GNC individuals should be aware of this possible association.
METHODS: Retrospective analysis of pancreatitis incidence rates in transgender and GNC persons exposed and not exposed to gender-affirming hormone therapy (GAHT).
RESULTS: 7 of the 1333 patients on hormone therapy had an incidence of pancreatitis. 0 of the 615 patients with no history of GAHT use developed pancreatitis. Representing a 6.96 (95% CI 2.76 to 848.78) for the development of pancreatitis in patients with exposure to GAHT therapy.
CONCLUSIONS: Clinicians working with GNC individuals should be aware of this possible association.
摘要：
背景：关于性别不合格（GNC）人群中胃肠道特异性病理发生率的数据有限。
方法：回顾性分析暴露和未暴露于性别确认激素治疗（GAHT）的变性人和GNC人群胰腺炎发生率。
结果：1333例接受激素治疗的患者中有7例发生胰腺炎。无GAHT使用史的615例患者中，有0例发展为胰腺炎。在接受GAHT治疗的患者中，胰腺炎的发展为6.96（95％CI2.76至848.78）。
结论：与GNC个体一起工作的临床医生应该意识到这种可能的关联。
方法：回顾性分析暴露和未暴露于性别确认激素治疗（GAHT）的变性人和GNC人群胰腺炎发生率。
结果：1333例接受激素治疗的患者中有7例发生胰腺炎。无GAHT使用史的615例患者中，有0例发展为胰腺炎。在接受GAHT治疗的患者中，胰腺炎的发展为6.96（95％CI2.76至848.78）。
结论：与GNC个体一起工作的临床医生应该意识到这种可能的关联。
